Loading...
Market
How much revenue will FILSPARI generate for Travere Therapeutics by Q1 2025?
2
Resolution / Starting Odds
Less than $50 million • 25%
$50 million to $100 million • 25%
$100 million to $150 million • 25%
More than $150 million • 25%
Company's quarterly earnings report
Story
Travere's FILSPARI for IgAN Wins FDA Approval, Stock Up 5.7%
Sep 6, 2024, 04:39 AM
Travere Therapeutics has announced that its drug FILSPARI (sparsentan) has received full approval from the FDA for treating IgA nephropathy (IgAN). FILSPARI is the only non-immunosuppressive treatment that significantly slows kidney function decline in patients with IgAN. Following the approval, Travere Therapeutics' stock (TVTX) saw a pre-market gain of 5.7%.
View original story
Similar markets
Less than $25 million • 25%
$25 million to $50 million • 25%
$50 million to $75 million • 25%
More than $75 million • 25%
Less than $50 million • 25%
$50 million - $100 million • 25%
$100 million - $150 million • 25%
More than $150 million • 25%
Less than 100 • 25%
100 - 500 • 25%
500 - 1000 • 25%
More than 1000 • 25%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $1.5 billion • 25%
More than $1.5 billion • 25%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $1.5 billion • 25%
More than $1.5 billion • 25%
Below $100 million • 25%
$100 million to $500 million • 25%
$500 million to $1 billion • 25%
Above $1 billion • 25%
Below $25 • 25%
$25 - $50 • 25%
$50 - $75 • 25%
Above $75 • 25%
Less than $200 million • 25%
$200 million to $300 million • 25%
$300 million to $400 million • 25%
More than $400 million • 25%
Less than $500 million • 33%
$500 million to $1 billion • 34%
More than $1 billion • 33%